Osmol Gap as a Surrogate Marker for Serum Propylene Glycol Concentrations in Patients Receiving Lorazepam for Sedation
- 6 January 2006
- journal article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 26 (1) , 23-33
Abstract
Study Objectives. To correlate serum propylene glycol concentration with osmol gap, serum lactate concentration, and amount of propylene glycol administered to mechanically ventilated patients receiving continuous infusions of lorazepam (80% propylene glycol by weight), and to characterize the prevalence of hyperosmolality and range of serum propylene glycol concentrations in this patient population.Design. Prospective, controlled, observational study.Setting. Adult surgical and cardiothoracic intensive care units (ICUs) of a 1200‐bed, urban, tertiary care, teaching hospital.Patients. Sixty‐four consecutively enrolled intensive care patients requiring mechanical ventilation and pharmacologic sedation.Intervention. Thirteen patients received continuous infusions of high‐dose lorazepam (≥ 6 mg/hr) for a minimum of 36 hours, and 26 received continuous infusions of low‐dose lorazepam (2–5.99 mg/hr) for 36 hours. Twenty‐five control patients received sedatives that did not contain propylene glycol.Measurements and Main Results. Serum propylene glycol and lactate concentrations, osmolality, and basic metabolic profiles were obtained 72–108 hours after ICU admission. Clinical data, drug administration, and severity of illness scores were recorded. Osmol gap and the amount of propylene glycol administered before serum sampling predicted propylene glycol concentrations (r2=0.692, p2=0.532, pConclusion. Osmol gap can be used as a surrogate marker for serum propylene glycol concentration. In critically ill patients receiving lorazepam for sedation, an osmol gap above 10 was associated with concentrations previously reported to cause toxicity.Keywords
This publication has 97 references indexed in Scilit:
- A Case of Plague Successfully Treated with Ciprofloxacin and Sympathetic Blockade for Treatment of GangreneClinical Infectious Diseases, 2003
- Removal of propylene glycol and correction of increased osmolar gap by hemodialysis in a patient on high dose lorazepam infusion therapyIntensive Care Medicine, 2001
- Hyperlactatemia, increased osmolar gap, and renal dysfunction during continuous lorazepam infusionCritical Care Medicine, 2000
- Propylene glycol dermatitisJournal of the American Academy of Dermatology, 1991
- Cerebral depression due to propylene glycol in a patient with chronic epilepsy--the value of the plasma osmolal gap in diagnosisPostgraduate Medical Journal, 1988
- Propylene Glycol Pharmacokinetics and Effects after Intravenous Infusion in HumansTherapeutic Drug Monitoring, 1987
- Pharmacokinetics of Propylene Glycol in Humans During Multiple Dosing RegimensJournal of Pharmaceutical Sciences, 1985
- Propylene glycol-induced heparin resistance during nitroglycerin infusionAmerican Heart Journal, 1985
- Central nervous system toxicity associated with ingestion of propylene glycolThe Journal of Pediatrics, 1978
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976